Trends in the receipt of guideline care and survival for women with ovarian cancer: A population-based study

Joan L. Warren, Linda C. Harlan, Edward Trimble, Jennifer Stevens, Melvin Grimes, Kathleen A. Cronin

Research output: Contribution to journalArticle

Abstract

Background We assessed trends in the receipt of guideline care and 2-year cause-specific survival for women diagnosed with ovarian cancer. Methods This retrospective cohort analysis used National Cancer Institute's Patterns of Care studies data for women diagnosed with ovarian cancer in 2002 and 2011 (weighted n = 6427). Data included patient characteristics, treatment type, and provider characteristics. We used logistic regression to evaluate the association of year of diagnosis with receipt of guideline surgery, multiagent chemotherapy, or both. Two-year cause-specific survival, 2002–2013, was assessed using SEER data. Results The adjusted rate of women who received stage-appropriate surgery, 48%, was unchanged from 2002 to 2011. Gynecologic oncologist (GO) consultations increased from 43% (2002) to 78% (2011). GO consultation was a significant predictor for receipt of guideline care, although only 40% of women who saw a GO received guideline surgery and chemotherapy. The percent of women who received guideline surgery and chemotherapy increased significantly from 32% in 2002 to 37% in 2011. From 2002 to 2011, 2-year cause-specific ovarian cancer survival was unchanged for Stages I-III cancers, with slight improvement for Stage IV cancers. Conclusion Receipt of guideline care has improved modestly from 2002–2011 for women with ovarian cancer. Current treatment is far below clinical recommendations and may explain limited improvement in 2-year cause-specific survival. Most women consulted a GO in 2011 yet did not receive guideline care. There needs to be a better understanding of the decision-making process about treatment during the consultation with GOs and other factors precluding receipt of guideline care.

Original languageEnglish (US)
Pages (from-to)486-492
Number of pages7
JournalGynecologic Oncology
Volume145
Issue number3
DOIs
StatePublished - Jun 1 2017
Externally publishedYes

Fingerprint

Ovarian Neoplasms
Guidelines
Survival
Population
Referral and Consultation
Drug Therapy
National Cancer Institute (U.S.)
Neoplasms
Decision Making
Cohort Studies
Therapeutics
Logistic Models
Oncologists

Keywords

  • Guideline care
  • Ovarian cancer
  • Survival
  • Treatment
  • Trends

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Trends in the receipt of guideline care and survival for women with ovarian cancer : A population-based study. / Warren, Joan L.; Harlan, Linda C.; Trimble, Edward; Stevens, Jennifer; Grimes, Melvin; Cronin, Kathleen A.

In: Gynecologic Oncology, Vol. 145, No. 3, 01.06.2017, p. 486-492.

Research output: Contribution to journalArticle

Warren, Joan L. ; Harlan, Linda C. ; Trimble, Edward ; Stevens, Jennifer ; Grimes, Melvin ; Cronin, Kathleen A. / Trends in the receipt of guideline care and survival for women with ovarian cancer : A population-based study. In: Gynecologic Oncology. 2017 ; Vol. 145, No. 3. pp. 486-492.
@article{5cd27fb2ab314a7a8587c4ca68137902,
title = "Trends in the receipt of guideline care and survival for women with ovarian cancer: A population-based study",
abstract = "Background We assessed trends in the receipt of guideline care and 2-year cause-specific survival for women diagnosed with ovarian cancer. Methods This retrospective cohort analysis used National Cancer Institute's Patterns of Care studies data for women diagnosed with ovarian cancer in 2002 and 2011 (weighted n = 6427). Data included patient characteristics, treatment type, and provider characteristics. We used logistic regression to evaluate the association of year of diagnosis with receipt of guideline surgery, multiagent chemotherapy, or both. Two-year cause-specific survival, 2002–2013, was assessed using SEER data. Results The adjusted rate of women who received stage-appropriate surgery, 48{\%}, was unchanged from 2002 to 2011. Gynecologic oncologist (GO) consultations increased from 43{\%} (2002) to 78{\%} (2011). GO consultation was a significant predictor for receipt of guideline care, although only 40{\%} of women who saw a GO received guideline surgery and chemotherapy. The percent of women who received guideline surgery and chemotherapy increased significantly from 32{\%} in 2002 to 37{\%} in 2011. From 2002 to 2011, 2-year cause-specific ovarian cancer survival was unchanged for Stages I-III cancers, with slight improvement for Stage IV cancers. Conclusion Receipt of guideline care has improved modestly from 2002–2011 for women with ovarian cancer. Current treatment is far below clinical recommendations and may explain limited improvement in 2-year cause-specific survival. Most women consulted a GO in 2011 yet did not receive guideline care. There needs to be a better understanding of the decision-making process about treatment during the consultation with GOs and other factors precluding receipt of guideline care.",
keywords = "Guideline care, Ovarian cancer, Survival, Treatment, Trends",
author = "Warren, {Joan L.} and Harlan, {Linda C.} and Edward Trimble and Jennifer Stevens and Melvin Grimes and Cronin, {Kathleen A.}",
year = "2017",
month = "6",
day = "1",
doi = "10.1016/j.ygyno.2017.03.016",
language = "English (US)",
volume = "145",
pages = "486--492",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Trends in the receipt of guideline care and survival for women with ovarian cancer

T2 - A population-based study

AU - Warren, Joan L.

AU - Harlan, Linda C.

AU - Trimble, Edward

AU - Stevens, Jennifer

AU - Grimes, Melvin

AU - Cronin, Kathleen A.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Background We assessed trends in the receipt of guideline care and 2-year cause-specific survival for women diagnosed with ovarian cancer. Methods This retrospective cohort analysis used National Cancer Institute's Patterns of Care studies data for women diagnosed with ovarian cancer in 2002 and 2011 (weighted n = 6427). Data included patient characteristics, treatment type, and provider characteristics. We used logistic regression to evaluate the association of year of diagnosis with receipt of guideline surgery, multiagent chemotherapy, or both. Two-year cause-specific survival, 2002–2013, was assessed using SEER data. Results The adjusted rate of women who received stage-appropriate surgery, 48%, was unchanged from 2002 to 2011. Gynecologic oncologist (GO) consultations increased from 43% (2002) to 78% (2011). GO consultation was a significant predictor for receipt of guideline care, although only 40% of women who saw a GO received guideline surgery and chemotherapy. The percent of women who received guideline surgery and chemotherapy increased significantly from 32% in 2002 to 37% in 2011. From 2002 to 2011, 2-year cause-specific ovarian cancer survival was unchanged for Stages I-III cancers, with slight improvement for Stage IV cancers. Conclusion Receipt of guideline care has improved modestly from 2002–2011 for women with ovarian cancer. Current treatment is far below clinical recommendations and may explain limited improvement in 2-year cause-specific survival. Most women consulted a GO in 2011 yet did not receive guideline care. There needs to be a better understanding of the decision-making process about treatment during the consultation with GOs and other factors precluding receipt of guideline care.

AB - Background We assessed trends in the receipt of guideline care and 2-year cause-specific survival for women diagnosed with ovarian cancer. Methods This retrospective cohort analysis used National Cancer Institute's Patterns of Care studies data for women diagnosed with ovarian cancer in 2002 and 2011 (weighted n = 6427). Data included patient characteristics, treatment type, and provider characteristics. We used logistic regression to evaluate the association of year of diagnosis with receipt of guideline surgery, multiagent chemotherapy, or both. Two-year cause-specific survival, 2002–2013, was assessed using SEER data. Results The adjusted rate of women who received stage-appropriate surgery, 48%, was unchanged from 2002 to 2011. Gynecologic oncologist (GO) consultations increased from 43% (2002) to 78% (2011). GO consultation was a significant predictor for receipt of guideline care, although only 40% of women who saw a GO received guideline surgery and chemotherapy. The percent of women who received guideline surgery and chemotherapy increased significantly from 32% in 2002 to 37% in 2011. From 2002 to 2011, 2-year cause-specific ovarian cancer survival was unchanged for Stages I-III cancers, with slight improvement for Stage IV cancers. Conclusion Receipt of guideline care has improved modestly from 2002–2011 for women with ovarian cancer. Current treatment is far below clinical recommendations and may explain limited improvement in 2-year cause-specific survival. Most women consulted a GO in 2011 yet did not receive guideline care. There needs to be a better understanding of the decision-making process about treatment during the consultation with GOs and other factors precluding receipt of guideline care.

KW - Guideline care

KW - Ovarian cancer

KW - Survival

KW - Treatment

KW - Trends

UR - http://www.scopus.com/inward/record.url?scp=85016418130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016418130&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2017.03.016

DO - 10.1016/j.ygyno.2017.03.016

M3 - Article

C2 - 28372872

AN - SCOPUS:85016418130

VL - 145

SP - 486

EP - 492

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -